These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9522984)

  • 41. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
    Aktaş G; Bozdoğan B; Derbentli S
    Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vancomycin-resistant enterococcal urinary tract infections.
    Heintz BH; Halilovic J; Christensen CL
    Pharmacotherapy; 2010 Nov; 30(11):1136-49. PubMed ID: 20973687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vancomycin-resistant enterococcus in end-stage renal disease.
    Brady JP; Snyder JW; Hasbargen JA
    Am J Kidney Dis; 1998 Sep; 32(3):415-8. PubMed ID: 9740157
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vancomycin-resistant enterococci in intensive care hospital settings.
    Austin DJ; Bonten MJ
    Mem Inst Oswaldo Cruz; 1998; 93(5):587-8. PubMed ID: 9830522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study.
    Lam S; Singer C; Tucci V; Morthland VH; Pfaller MA; Isenberg HD
    Am J Infect Control; 1995 Jun; 23(3):170-80. PubMed ID: 7677262
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of systemic bacteraemia after oral inoculation of vancomycin-resistant enterococci in mice.
    Miyazaki S; Fujikawa T; Kobayashi I; Matsumoto T; Tateda K; Yamaguchi K
    J Med Microbiol; 2001 Aug; 50(8):695-701. PubMed ID: 11478673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [What is to be done with vancomycin-resistant enterococcal infections?].
    Bonten MJ; Mascini EM; Willems R; Timmer GJ; Gaillard CA; Vandenbroucke-Grauls CM
    Ned Tijdschr Geneeskd; 2000 Dec; 144(53):2545-9. PubMed ID: 11191789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of vancomycin, linezolid, and daptomycin against staphylococci and enterococci isolated in 5 Greek hospitals during a 5-year period (2008-2012).
    Papadimitriou-Olivgeris M; Kolonitsiou F; Zerva L; Lebessi E; Koutsia C; Drougka E; Sarrou S; Giormezis N; Vourli S; Doudoulakakis A; Konsolakis C; Marangos M; Anastassiou ED; Petinaki E; Spiliopoulou I
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):386-8. PubMed ID: 26341703
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vancomycin-resistant enterococcus. Detection, epidemiology, and control measures.
    Boyce JM
    Infect Dis Clin North Am; 1997 Jun; 11(2):367-84. PubMed ID: 9187952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Epidemiological search for vancomycin-resistant enterococci in mainland of the Ryukyus].
    Kisanuki K; Higa M; Nakasone I; Shiohira CM; Yamane N
    Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2008; 19(1-2):1-6. PubMed ID: 19583456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [In vitro activity of daptomycin against VRE and MRSA strains].
    Aktaş G; Derbentli S
    Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of vancomycin-resistant enterococci in Europe.
    Schouten MA; Hoogkamp-Korstanje JA; Meis JF; Voss A;
    Eur J Clin Microbiol Infect Dis; 2000 Nov; 19(11):816-22. PubMed ID: 11152305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Evaluation of antimicrobial sensitivity of 87 clinical isolates of vancomycin-resistant enterococci].
    Saraiva IH; Jones RN; Erwin M; Sader HS
    Rev Assoc Med Bras (1992); 1997; 43(3):217-22. PubMed ID: 9497549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emergence of vancomycin-resistant enterococci.
    Rice LB
    Emerg Infect Dis; 2001; 7(2):183-7. PubMed ID: 11294702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Vancomycin resistant Enterococci (VRE)].
    Lesens O
    Nephrol Ther; 2009 Jun; 5 Suppl 4():S261-4. PubMed ID: 19596346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emergence of vancomycin-resistant enterococci in New York City.
    Frieden TR; Munsiff SS; Low DE; Willey BM; Williams G; Faur Y; Eisner W; Warren S; Kreiswirth B
    Lancet; 1993 Jul; 342(8863):76-9. PubMed ID: 8100912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates.
    Bell JM; Paton JC; Turnidge J
    J Clin Microbiol; 1998 Aug; 36(8):2187-90. PubMed ID: 9665988
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emergence of vancomycin-resistant enterococci in Switzerland: a nation-wide survey.
    Buetti N; Wassilew N; Rion V; Senn L; Gardiol C; Widmer A; Marschall J;
    Antimicrob Resist Infect Control; 2019; 8():16. PubMed ID: 30675343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit.
    Malik RK; Montecalvo MA; Reale MR; Li K; Maw M; Munoz JL; Gedris C; van Horn K; Carnevale KA; Levi MH; Dweck HS
    Pediatr Infect Dis J; 1999 Apr; 18(4):352-6. PubMed ID: 10223689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.